Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Edward Damiano
Boston University (Charles River Campus), Department: Engineering (All Types)
Should you be removed from our database? Contact us at [email protected]. Read more below.
Beta Bionics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
See attachment
Final clinical studies for submission of a pre-market approval application to the FDA for a Bionic Pancreas that automates type 1 diabetes management
Good, consistent management of blood sugar levels in people with type 1 diabetes is essential to preventing and minimizing health complications. Our goal is to conduct the ?nal (pivotal) clinical trial to test a new fully integrated and wearable bionic pancreas medical device that will automatically manage blood sugar levels in people with type 1 diabetes and thus reduce the burden of diabetes care; this trial will provide all clinical results needed to submit a pre-market approval application to the US FDA. The study will comprehensively test the hypothesis that our bionic pancreas device, which integrates (1) a glucose-sensing device that automatically and frequently estimates blood sugar levels, (2) decision software that automatically determines therapeutic dosing requirements, and (3) a dual-infusion system that automatically delivers insulin to lower blood sugar levels and glucagon to raise blood sugar levels, will provide effective and safe management of blood sugar levels in people with type 1 diabetes and, as a consequence, will dramatically reduce the risk of health complications that often arise with type 1 diabetes.
Filed on March 22, 2016.
Tell us what you know about Edward Damiano's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Edward Damiano filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Edward Damiano | Boston University (Charles River Campus) | Conflict of Interest | Beta Bionics | Value cannot be readily determined |
| Edward Damiano | Boston University (Charles River Campus) | Conflict of Interest | Beta Bionics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.